Bodhi was engaged to carry out an endline evaluation of the four-year Gavi 5.0 Programme (2022–2026), the most recent phase of the partnership between Girl Effect (GE) and Gavi concerning routine childhood immunisation (RI) and the generation of demand for the human papillomavirus (HPV) vaccine. The evaluation focused on the second implementation phase, from 2023 to 2025, and looked at three areas in Tanzania: Lindi, Katavi and Tabora. Both the HPV vaccines and routine immunisation have important health benefits as well as positive economic effects. Since Sub-Saharan Africa has the highest rates of cervical HPV prevalence amongst women globally, the need for immunisation is crucial. Bodhi assessed the effect of GE's intervention on the factors that influence, the intentions and the actual uptake of the HPV vaccine among eligible girls and on the factors that influence, the intentions and the actual uptake of routine immunisation within the target populations in both countries. In order to provide a clear understanding of the programme's results, Bodhi gathered quantitative data compared with the baseline, as well as qualitative data to assess the programme's effectiveness, efficiency, impact and sustainability. Finally, Bodhi gave recommendations, recorded the lessons learned and pointed out best practices for the next phase as well as for other similar programmes.